5-fu

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Solid TumorGastric AdenocarcinomaEsophageal AdenocarcinomaCervical CarcinomaPleural MesotheliomaMalignant Solid TumorGastrointestinal Cancer

171 competitors in Solid Tumor

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

82

Lenvima

Eisai

Phase 3

33

Lynparza

AstraZeneca

Phase 3

14

Bavencio

EMD Serono

Phase 3

15

5-fu

TToray Industries, Inc

Phase 3

26

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

17

MK-4280

Merck & Co.

Phase 3

18

MK-4280A

Merck & Co.

Phase 3

19

INCB161734

Incyte

Phase 3

110

Abraxane

Bristol-Myers Squibb

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Solid Tumor2 trials

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting·CCStone Pharmaceuticals·Preclinical·NCT06741644·660 enrolled

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Active, not recruiting·TToray Industries, Inc·Phase 1·NCT03872947·138 enrolled

Malignant Solid Tumor1 trial

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Active, not recruiting·Genmab·Preclinical·NCT04083599·350 enrolled

Cervical Carcinoma1 trial

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Recruiting·AstraZeneca·Phase 2·NCT06535607·257 enrolled

Gastrointestinal Cancer1 trial

A Phase Ib/IIa Clinical Trial Evaluating the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors

Recruiting·ZZhejiang Doer Biologics Co., Ltd.·Preclinical·NCT07056777·186 enrolled

Pleural Mesothelioma1 trial

A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07532902·60 enrolled

2 more indications

Gastric Adenocarcinoma1 trial

A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 Plus Chemotherapy (CAPOX or mFOLFOX6) With Pembrolizumab vs Placebo Plus Chemotherapy With or Without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive

Not yet recruiting·Astellas·Phase 3·NCT07673887·570 enrolled

Esophageal Adenocarcinoma1 trial

Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04150640·52 enrolled

Details

Drug Info

Related News